





Date: 08 November 2023

| То | То |
|---------------------------|--|
| BSE Limited | National Stock Exchange of India Limited |
| Phiroze Jeejeebhoy Towers | Exchange Plaza |
| Dalal Street | Bandra Kurla Complex |
| Mumbai- 400001 | Bandra (E) |
| | Mumbai-400051 |
| Security Code: 540596 | Symbol: ERIS |

SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("LODR") we hereby inform you that the Company has entered into an agreement to acquire the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics Limited to the extent and in the manner mentioned therein.

In accordance with the requirement of SEBI LODR read with Para B (5) of Part A of Schedule III and SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, the enclosed details may be taken on record.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer







Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business) and revision(s) or amendment(s) or termination(s) thereof:

| Agreeme | Agreement: | | |
|---------|---|---|--|
| a) | Name(s) of parties with whom the agreement is entered | Eris Lifesciences Limited and Biocon Biologics Limited | |
| b) | Purpose of entering into the agreement | Eris' purpose of entering into the agreement is two-fold: Enter the Nephrology therapy through a platform consisting of established brands and a Sales & Marketing team Augment product portfolio and market reach in the Dermatology therapy | |
| c) | Shareholding, if any, in the entity with whom the agreement is executed | The Company does not hold any shareholding in the entity with whom the agreement is executed. | |
| d) | Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc. | Not Applicable | |
| e) | Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship | No party to the agreement is related to promoter/promoter group or group companies in any manner. | |
| f) | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length". | Not Applicable | |
| g) | in case of issuance of shares to the parties, details of issue price, class of shares issued | No shares are issued under the executed agreement. | |
| h) | any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc | Not Applicable | |







| i) | in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): | Not Applicable |
|----|--|----------------|
| | a)name of parties to the agreement; b)nature of the agreement; c)date of execution of the agreement; d)details of amendment and impact thereof or reasons of termination and impact thereof. | |